Biobeat BB-613: FDA-Cleared Cuffless Blood Pressure Monitoring for Clinical Care

The first FDA-cleared cuffless blood pressure monitor designed for hospital and remote patient monitoring brings continuous hemodynamic surveillance to patients who need it most.

Presented By Our Partners

Blood pressure is measured billions of times each year in clinical settings worldwide, yet the fundamental technology has barely changed in over a century. An inflatable cuff occludes arterial blood flow, a sensor detects the return of pulsatile flow, and two numbers are recorded: systolic and diastolic. The measurement is accurate at the moment it is taken, but it captures only a single snapshot of a continuously fluctuating physiological parameter. A 2019 study published in Hypertension by Drawz et al. demonstrated that office blood pressure readings missed nocturnal hypertension in 30% to 50% of patients studied, a pattern strongly associated with increased cardiovascular and renal risk. The clinical problem is not measurement accuracy; it is measurement frequency.

Biobeat, an Israeli medical technology company, has attempted to solve this problem with the BB-613, a chest-worn patch that delivers continuous, cuffless blood pressure monitoring alongside a comprehensive suite of hemodynamic parameters. FDA cleared for clinical use, the BB-613 represents one of the first validated cuffless blood pressure devices designed specifically for hospital patients and remote clinical monitoring, rather than consumer wellness tracking.

What Is the Biobeat BB-613?

The Biobeat BB-613 is a disposable, medical-grade chest patch that continuously monitors blood pressure without a traditional inflatable cuff. The device uses photoplethysmography (PPG) sensors combined with proprietary algorithms to derive blood pressure measurements from pulse wave analysis, capturing beat-to-beat variations in arterial pressure that cuff-based intermittent measurements inherently miss.

Beyond blood pressure, the BB-613 simultaneously monitors heart rate, respiratory rate, blood oxygen saturation (SpO2), heart rate variability, cardiac output, and skin temperature. This multi-parameter capability positions it as a comprehensive hemodynamic monitoring platform rather than a single-purpose blood pressure device. Data transmits wirelessly to a centralized clinical dashboard where care teams can monitor patients in real time, with configurable alert thresholds that trigger notifications when vital signs move outside prescribed ranges.

The device is designed for clinical environments: hospitals, post-surgical recovery units, skilled nursing facilities, and physician-supervised remote patient monitoring programs. It is not a consumer product available for direct purchase. Healthcare facilities acquire the system through Biobeat’s clinical sales channel, with pricing determined by institutional contracts and monitoring volume.

The Science Behind Cuffless Blood Pressure Monitoring

The clinical case for continuous blood pressure monitoring rests on decades of evidence demonstrating that intermittent measurements, even when taken frequently, fail to capture the full hemodynamic picture. Ambulatory blood pressure monitoring (ABPM) studies have consistently shown that 24-hour blood pressure patterns predict cardiovascular outcomes more accurately than office-based readings. A landmark meta-analysis published in The Lancet by Staplin et al. in 2023, encompassing data from over 27,000 patients, confirmed that ambulatory blood pressure measurements were superior to clinic measurements in predicting cardiovascular events, with nocturnal blood pressure proving the strongest independent predictor of adverse outcomes.

The phenomenon of masked hypertension, where patients display normal blood pressure in clinical settings but elevated readings during daily life, affects an estimated 10% to 15% of the general adult population. A 2020 study published in the Journal of the American College of Cardiology by Cohen et al. found that masked hypertension was associated with a 2.09-fold increased risk of major cardiovascular events compared to sustained normotension, making it a clinically significant and dangerously underdiagnosed condition.

Cuffless blood pressure technology attempts to make continuous measurement practical by eliminating the cuff entirely. The PPG-based approach measures changes in blood volume at the skin surface, which correlate with arterial pressure waves. Pulse transit time (the interval between the heart’s electrical activity and the arrival of the pulse wave at a peripheral site) and pulse wave morphology (the shape of the arterial pressure waveform) both contain information about vascular stiffness and blood pressure that algorithms can extract.

The validation challenge for cuffless devices is substantial. The IEEE 1708 standard and the Association for the Advancement of Medical Instrumentation (AAMI) protocols define accuracy requirements for blood pressure devices, typically requiring mean differences within 5 mmHg and standard deviations below 8 mmHg when compared to reference standards. Biobeat has published validation studies showing the BB-613 meets these accuracy thresholds in controlled clinical settings, though real-world performance across diverse patient populations continues to be evaluated.

Within the broader context of cardiovascular disease, one of the Four Shadows identified in Healthcare Discovery‘s longevity framework, continuous blood pressure monitoring represents a fundamental shift from reactive to proactive cardiovascular management. Hypertension remains the single most modifiable risk factor for heart disease and stroke, and the ability to track it continuously rather than intermittently could transform both inpatient care and chronic disease management.

What the BB-613 Does Well

The BB-613’s primary achievement is its FDA clearance for cuffless blood pressure monitoring in a clinical context. While several consumer companies have announced cuffless blood pressure features, the Biobeat device is one of very few that have achieved regulatory clearance for clinical-grade measurements. This distinction matters enormously: the difference between a wellness estimate and a clinical measurement that physicians can use for treatment decisions is the difference between informational and actionable data.

The multi-parameter monitoring capability transforms the device from a blood pressure monitor into a hemodynamic surveillance platform. Capturing heart rate, respiratory rate, SpO2, cardiac output, and HRV alongside continuous blood pressure provides a richer clinical picture than any single-parameter monitor can deliver. For post-surgical patients or those in step-down units transitioning from ICU-level monitoring, the BB-613 can maintain comprehensive vital sign surveillance without the tethered cables and bulky equipment of traditional bedside monitors.

The wireless, patch-based form factor promotes patient mobility, which is itself a therapeutic intervention. Early mobilization after surgery is associated with shorter hospital stays and reduced complication rates. A monitoring device that moves with the patient, rather than confining them to a bedside monitor, supports the clinical goal of getting patients up and moving sooner.

The centralized dashboard with configurable alerts enables proactive clinical intervention. Rather than discovering concerning vital sign trends during scheduled nursing rounds, care teams receive real-time notifications that can trigger earlier assessment and intervention.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Pricing, Access, and Practical Realities

The Biobeat BB-613 is a clinical product with institutional pricing. Individual consumers cannot purchase the device directly. Healthcare facilities, hospital systems, and remote patient monitoring programs acquire the system through Biobeat’s commercial team, with pricing structured around device volume, monitoring duration, and integration requirements. Specific pricing is not publicly disclosed and varies by contract.

For patients, the cost of monitoring is typically embedded in the overall cost of care, whether inpatient hospital charges, post-acute facility fees, or physician-supervised remote monitoring programs billed under established RPM CPT codes. Patients generally do not receive a separate bill for the Biobeat device itself.

The FDA clearance covers the device as a cuffless blood pressure monitor and multi-parameter vital sign monitoring system. It is important to distinguish this from consumer-grade blood pressure estimates offered by smartwatches and fitness trackers, which typically carry “general wellness” designations rather than FDA clearance for clinical blood pressure measurement. The BB-613’s regulatory pathway positions it as a medical device with clinical-grade accuracy expectations, not a wellness product with informational outputs.

HSA and FSA eligibility is generally not applicable for the BB-613 because patients do not directly purchase the device. The monitoring cost is part of clinical care billing, which flows through standard insurance and payment channels.

Who It Is Best For

The BB-613 is designed for clinical populations requiring continuous hemodynamic monitoring. The primary use cases include post-surgical patients transitioning from ICU to step-down or general ward care, where comprehensive monitoring needs to continue without ICU-level staffing ratios. Patients with hypertensive emergencies or unstable blood pressure requiring continuous surveillance rather than intermittent cuff checks represent another core population.

Remote patient monitoring programs for high-risk cardiac patients, particularly those with heart failure or resistant hypertension, can leverage the device for physician-supervised home monitoring that captures the continuous blood pressure data that intermittent office visits miss.

Skilled nursing facilities and rehabilitation centers monitoring medically complex patients during recovery periods may find the multi-parameter wireless platform more practical than traditional wired monitoring systems.

The BB-613 is not intended for healthy individuals seeking blood pressure wellness tracking. Consumers interested in personal blood pressure monitoring should consider validated home cuff monitors (which remain the gold standard for self-measurement) or explore emerging consumer cuffless devices, keeping in mind that most consumer options lack the clinical validation of devices like the BB-613.

How It Compares

In the clinical cuffless blood pressure space, the BB-613’s closest comparators are traditional ambulatory blood pressure monitors (ABPM) and emerging cuffless competitors. Standard ABPM devices like the Spacelabs 90217A have been the reference standard for out-of-office blood pressure assessment for decades, but they use miniaturized inflatable cuffs that inflate periodically (typically every 15 to 30 minutes), causing patient discomfort and sleep disruption that can itself alter blood pressure readings. The Biobeat approach eliminates cuff inflation entirely, enabling truly continuous measurement without the periodic compression artifact.

The Masimo W1 Wearable, another clinical-grade device in the same clinical professional category, focuses on SpO2 monitoring with Masimo’s industry-leading SET pulse oximetry technology but does not offer cuffless blood pressure. For facilities prioritizing oxygen saturation accuracy (post-surgical respiratory monitoring, for example), the Masimo W1 may be the stronger choice for that specific parameter, while the BB-613 offers broader hemodynamic coverage.

On the consumer side, Samsung has introduced blood pressure estimation in certain Galaxy Watch models (cleared in some international markets but not widely FDA cleared in the United States for clinical use), and several startups are pursuing cuffless BP technology. However, none of these consumer devices have achieved the clinical-grade FDA clearance that the BB-613 holds, making direct comparison inappropriate. They serve fundamentally different purposes: consumer awareness versus clinical decision support.

Limitations and Open Questions

Cuffless blood pressure technology remains an evolving field, and even FDA-cleared devices face ongoing questions about accuracy across diverse patient populations. Factors including skin pigmentation, body composition, arterial stiffness variations, and patient movement can all influence PPG-based measurements. Long-term validation studies across broader demographics will be essential for establishing the technology’s reliability in routine clinical practice.

The requirement for periodic calibration against a reference cuff measurement is a practical limitation. Most cuffless BP devices, including PPG-based systems, require initial calibration and periodic recalibration against a standard cuff reading to maintain accuracy. This does not eliminate the cuff; it reduces the frequency of cuff use while enabling continuous monitoring between calibration points.

Data integration with existing electronic health record (EHR) systems varies by institution. Seamless EHR integration is essential for the monitoring data to flow into clinical workflows without creating additional documentation burden for care teams.

The disposable patch model raises sustainability questions as healthcare systems increasingly evaluate the environmental impact of single-use medical devices. The trade-off between infection control benefits (no device reprocessing required) and waste generation is a consideration for institutional purchasers.

What This Means for Your Health

Hypertension is the most prevalent modifiable risk factor for cardiovascular disease, affecting nearly half of American adults. Yet blood pressure management remains stubbornly suboptimal, in part because the measurement paradigm has relied on sporadic snapshots rather than continuous surveillance. The Biobeat BB-613 represents a clinical-grade step toward solving that measurement gap, bringing continuous blood pressure data to the patients who need it most: those in hospitals, post-surgical recovery, and physician-supervised remote monitoring programs.

For the broader population, the BB-613’s significance lies not in direct consumer access but in what it signals about the trajectory of cardiovascular monitoring. The technology that begins in hospitals eventually migrates to clinics, then to homes, then to wearables. The validation work being done with devices like the BB-613 lays the regulatory and clinical evidence foundation that future consumer cuffless blood pressure devices will build upon.

Within HealthcareDiscovery.ai’s Five Pillars framework, blood pressure connects to virtually every pillar. Nutrition (sodium intake, potassium balance, metabolic health), Movement (aerobic exercise reduces systolic BP by 5 to 8 mmHg on average), Sleep (nocturnal blood pressure dipping is a marker of cardiovascular health), Breathwork (slow breathing techniques have demonstrated acute blood pressure reduction in controlled studies), and Mindset (chronic psychological stress elevates blood pressure through sustained sympathetic activation) all influence the hemodynamic measurements the BB-613 captures. Continuous monitoring makes these connections visible in ways that intermittent measurement never could.

The future of blood pressure management is continuous, personalized, and proactive. The BB-613 is a clinical-grade tool serving that future today.

Explore the full wearable guide

See how the Biobeat BB-613 compares with smart rings, watches, ECG devices, and other connected health hardware across the full Healthcare Discovery wearables guide.

Frequently Asked Questions

What is the Biobeat BB-613 and how does it measure blood pressure without a cuff?
The Biobeat BB-613 is an FDA-cleared chest-worn patch that uses photoplethysmography (PPG) sensors and proprietary algorithms to derive continuous blood pressure measurements from pulse wave analysis. Instead of inflating a cuff to occlude arterial flow, the device analyzes the shape, timing, and amplitude of blood volume changes at the skin surface, which correlate with arterial pressure. It simultaneously monitors heart rate, respiratory rate, SpO2, HRV, cardiac output, and skin temperature, providing comprehensive hemodynamic surveillance in a wireless, adhesive patch form factor.

Is the Biobeat BB-613 available for consumers to purchase?
No. The BB-613 is a clinical-grade medical device designed for use in hospitals, post-acute care facilities, and physician-supervised remote patient monitoring programs. It is not available for direct consumer purchase. Healthcare institutions acquire the system through Biobeat’s commercial sales channel with institutional pricing determined by contract. Patients who are monitored with the device encounter it as part of their clinical care, not as a personal purchase.

How accurate is cuffless blood pressure monitoring compared to traditional cuffs?
Biobeat has published validation studies demonstrating that the BB-613 meets AAMI (Association for the Advancement of Medical Instrumentation) accuracy standards, with mean differences within 5 mmHg and standard deviations below 8 mmHg compared to reference cuff measurements. However, cuffless BP technology is still evolving, and accuracy can be influenced by factors including patient movement, skin pigmentation, and vascular stiffness. Periodic calibration against a traditional cuff reading is typically required to maintain measurement accuracy over time.

What parameters does the BB-613 monitor besides blood pressure?
The BB-613 functions as a multi-parameter hemodynamic monitoring platform. In addition to continuous cuffless blood pressure, it simultaneously measures heart rate, respiratory rate, blood oxygen saturation (SpO2), heart rate variability (HRV), cardiac output, and skin temperature. All parameters transmit wirelessly to a centralized clinical dashboard with configurable alert thresholds, enabling care teams to monitor patients in real time and receive notifications when vital signs deviate from prescribed ranges.

How does the Biobeat BB-613 compare to the Apple Watch blood pressure feature?
The two devices serve entirely different purposes. The BB-613 is an FDA-cleared clinical medical device designed for hospital and physician-supervised monitoring, with validation studies demonstrating clinical-grade accuracy. Consumer devices like the Apple Watch that offer blood pressure estimation typically carry general wellness designations rather than clinical-grade FDA clearance, and their measurements are intended for informational awareness rather than clinical treatment decisions. The BB-613 produces data that physicians use to adjust medications and make treatment decisions; consumer estimates are not validated for that purpose.

Does the BB-613 require calibration?
Yes. Like most cuffless blood pressure devices, the BB-613 requires initial calibration and periodic recalibration against a standard cuff-based blood pressure measurement to maintain accuracy. This means cuff-based measurement is not fully eliminated but rather reduced in frequency, with continuous cuffless monitoring filling the gaps between calibration points. The calibration frequency depends on the clinical protocol and monitoring duration.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.